Kidney disease — all decisions

The appeal was dismissed due to the Veteran's death during its pendency.

The Board granted an initial evaluation not to exceed 30 percent for adjustment disorder with mixed anxiety and depressed mood for the period prior to August 8, 2023, but denied a higher rating since that date. The other service connection claims were remanded.

The Board granted an effective date of March 8, 2023 for the award of service connection for plantar fasciitis. The claims for angina pectoris, kidney disability, liver disability, and skin cancer were remanded.

The Board remands the claims for service connection of thymoma and tumors/cysts of the liver, kidneys, and pancreas to obtain an addendum opinion addressing their relationship to in-service exposure to herbicide agents.

The Board remands the claims for service connection for chronic obstructive pulmonary disease, a prostate disability, and chronic kidney disease for further development of the record.

The Veteran's service connection for bilateral hearing loss was granted, while claims for other conditions such as chronic fatigue syndrome, headaches, a heart disorder, hypertension, irritable colon syndrome, kidney removal, kidney cancer, liver disorder, lung disorder, renal disease, sleep apnea, stomach disorder, and stress disorder were denied.

The Board remands the claims for service connection for impaired fasting glucose claimed as diabetes mellitus and a kidney condition due to an inadequate medical opinion.

The Board has granted service connection for hypertension, kidney disease, and cerebrovascular accident due to the Veteran's preexisting hypertension being permanently aggravated during active service.

The appeals for service connection for chronic kidney disease, left kidney radical nephrectomy, status post clear cell carcinoma, and lung cancer have been withdrawn by the Veteran's attorney.

The Board granted service connection for diabetes mellitus type II with erectile dysfunction, left foot peripheral neuropathy of the sciatic nerve, and hypertension, effective from November 2, 2022. Other claims were denied.

The Board remands the claim for an initial compensable evaluation of chronic kidney disease stage IV to obtain a new VA opinion addressing the beginning of the Veteran's loss of kidney function and whether a baseline date of disability can be established.

The Board remands the case for a new medical opinion to address whether the Veteran's kidney disease is related to in-service toxic exposure, specifically naphthalene.

The Board denied service connection for prostate cancer, renal failure, and hypertension as there is no evidence linking these conditions to the Veteran's military service or toxic exposure at Camp Lejeune.

The Board denied earlier effective dates for the awards of service connection for muscle group XII substance loss, status post chondrosarcoma of the right lower extremity; chondrosarcoma of the lungs; and left kidney removal, status post chondrosarcoma.

The Board denied the Veteran's claim for service connection for a renal condition, finding no evidence that it was related to his active-duty service or exposure to contaminated water at Camp Lejeune.

The Board denied the claim for service connection for the cause of the Veteran's death, as sepsis and liver disease were not shown to be related to his service or any incident during it.

The Board granted service connection for tinnitus and remanded the claims for kidney failure and bilateral hearing loss due to a duty to assist error.

The Board denied service connection for a seizure disorder and chronic kidney disease as the evidence did not support a causal relationship between these conditions and the Veteran's period of active service.

The Board remands the issues of earlier effective dates and evaluations for migraine with chronic right-sided headaches and ureterolithiasis with kidney stones with left renal colic due to a pre-decisional duty to assist error.

The Board granted service connection for chronic kidney disease, which is related to the Veteran's service-connected hypertension. The other claims were remanded for further development.